Krystal Biotech

Krystal Biotech, based in Pittsburgh, the United States, is a biotechnology company listed as NASDAQ: KRYS. Krystal Biotech develops redosable genetic medicines using a proprietary, replication-defective, non-integrating modified HSV-1 vector platform for severe, life-threatening or rare diseases. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing KB707 in non-small-cell lung cancer and melanoma. The largest, NCT06228326 (A Study Assessing KB707 for the Treatment of Advanced Solid Tumour Malignancies Affecting the Lungs), plans to enrol 250 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.